Streetbeat News

Regulatory

GCTK

Glucotrack has been granted an additional 180-day period by Nasdaq to regain compliance with listing requirements. The company now has until May 20, 2024, to meet the standards necessary to maintain its listing on the exchange.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 10:43 pm

BCE

Bell has acquired 3800 MHz licenses in a Canadian auction, which could potentially enhance their telecommunications infrastructure and service offerings. BCE Inc. (BCE), the parent company of Bell, may be impacted by this news.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 10:42 pm

PFE

Texas Attorney General Ken Paxton has filed a lawsuit against Pfizer Inc. for allegedly misrepresenting the efficacy of its COVID-19 vaccine and attempting to censor public discourse. The lawsuit claims Pfizer engaged in deceptive practices by promoting the vaccine's 95% efficacy based on relative risk reduction, which is considered misleading. It also accuses Pfizer of suppressing information about the vaccine's limited duration of protection and failing to measure its effect on transmission. The lawsuit alleges that Pfizer tried to silence critics when the vaccine's limitations became apparent.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 10:39 pm

BYON

Beyond Board has unanimously voted to enhance governance and accountability by declassifying its board structure. This move is aimed at making the company's governance more democratic and could potentially lead to more direct influence by shareholders on board decisions.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 10:31 pm

LDO

UNI

Rollbit, a crypto casino and futures exchange, has a market cap of $505M and YTD revenue of $355M. It ranks third in revenue among crypto protocols, behind Uniswap and Lido. Rollbit's diverse revenue streams and token buyback program have contributed to its success, with a significant portion of RLB tokens already burned. Despite rapid revenue growth and a favorable P/S ratio, potential investors should consider risks such as the platform's anonymity and licensing in Curaçao, as well as restrictions in major markets.

Portfolio Pulse from Murtuza Merchant

November 30, 2023 | 10:31 pm

JPM

JPMorgan's research report indicates a resurgence in the DeFi and NFT sectors, driven by the anticipation of a U.S.-based spot Bitcoin ETF. The report notes increased trading activity in DeFi, the rise of liquid staking, and the emergence of new chains and protocols. However, it also mentions Ethereum's ongoing challenges with scalability and competition. The overall sentiment is cautiously optimistic about the revival of DeFi and NFT activities.

Portfolio Pulse from Murtuza Merchant

November 30, 2023 | 10:20 pm

MRK

SGEN

Seagen announced that the FDA has granted priority review for the sBLA of PADCEV in combination with KEYTRUDA for the first-line treatment of advanced bladder cancer. This could expedite the approval process, potentially benefiting patients with advanced bladder cancer.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 10:03 pm

MRK

Merck announced that the FDA has granted priority review to their application for KEYTRUDA in combination with Padcev for the first-line treatment of patients with locally advanced or metastatic urothelial cancer.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 10:01 pm

BTCUSD

A Bitcoin wallet address that accumulated over 10,000 BTC since November has been identified as a cold wallet owned by BitMEX. The address became the 74th largest Bitcoin holder, sparking speculation it was a new entity amid optimism for spot bitcoin ETFs in the U.S. However, it was revealed that BitMEX is transferring its holdings to a new address format supporting SegWit for more efficient transactions. BTC prices have risen 9% in the past month and are trading flat after exceeding $38,000.

Portfolio Pulse from Khyathi Dalal

November 30, 2023 | 9:57 pm

BIOR

Biora Therapeutics has received FDA clearance for its IND application for BT-600, a drug/device combination using Biora's NaviCap ingestible drug delivery device with tofacitinib, aimed at treating moderate to severe ulcerative colitis.

Portfolio Pulse from Benzinga Newsdesk

November 30, 2023 | 9:49 pm